Iqvia Holdings Inc.

IQV

US46266C1053

Biotechnology & Medical Research

Delayed Nyse Other stock markets 03:47:48 2024-12-03 pm EST			5-day change	1st Jan Change
200.78 ^USD	-0.50%		-0.24%	-13.24%

Dec. 02	Nephron Upgrades IQVIA Holdings to Buy, Price Target is $250	MT
Dec. 02	Nephron Research Upgrades IQVIA to Buy, Price Target is $250	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Iqvia Holdings Inc.

Nephron Upgrades IQVIA Holdings to Buy, Price Target is $250	Dec. 02	MT
Nephron Research Upgrades IQVIA to Buy, Price Target is $250	Dec. 02	MT
Goldman Sachs Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Buy Rating	Nov. 26	MT
Redburn Atlantic Adjusts Price Target on IQVIA Holdings to $255 From $276, Maintains Buy Rating	Nov. 25	MT
Baird Adjusts Price Target on IQVIA Holdings to $213 From $223, Maintains Neutral Rating	Nov. 25	MT
Leerink Adjusts Price Target on IQVIA Holdings to $248 From $260, Maintains Outperform Rating	Nov. 19	MT
IQVIA Holdings Inc. Presents at UBS Global Healthcare Conference 2024, Nov-13-2024 10:15 AM	Nov. 13
Argus Cuts Price Target on IQVIA to $260 From $280	Nov. 06	MT
JPMorgan Cuts Price Target on IQVIA to $240 From $279, Maintains Overweight Rating	Nov. 05	MT
UBS Adjusts Price Target on IQVIA to $260 From $300, Maintains Buy Rating	Nov. 01	MT
Citigroup Adjusts Price Target on IQVIA to $225 From $250	Nov. 01	MT
Jefferies Adjusts Price Target on IQVIA to $195 From $242	Nov. 01	MT
BTIG Adjusts Price Target on IQVIA to $260 From $290	Nov. 01	MT
Baird Adjusts Price Target on IQVIA to $223 From $256	Nov. 01	MT
Barclays Adjusts Price Target on IQVIA to $255 From $260	Nov. 01	MT
Goldman Sachs Adjusts Price Target on IQVIA to $250 From $280	Nov. 01	MT
Deutsche Bank Adjusts Price Target on IQVIA to $265 From $270	Nov. 01	MT
Evercore ISI Adjusts Price Target on IQVIA to $235 From $265	Nov. 01	MT
Leerink Partners Adjusts Price Target on IQVIA to $260 From $270	Nov. 01	MT
Stifel Adjusts Price Target on IQVIA to $273 From $312	Nov. 01	MT
TD Cowen Adjusts Price Target on IQVIA to $255 From $270	Nov. 01	MT
Truist Cuts Price Target on IQVIA Holdings to $265 From $286, Maintains Buy Rating	Nov. 01	MT
Analyst recommendations: Amazon.com, Mastercard, Bristol-Myers Squibb Company, Uber Technologies, Regeneron Pharmaceuticals...	Nov. 01
Deutsche Bank Trims Price Target on IQVIA Holdings to $265 From $270, Keeps Buy Rating	Nov. 01	MT
Sector Update: Health Care Stocks Lower to Flat Premarket Thursday	Oct. 31	MT

Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).

Employees

88,000

Sector

Biotechnology & Medical Research

Calendar

2024-12-10 - Investor Day

More about the company